

Mymetics strengthens virosome vaccine platform

Epalinges, Switzerland, March 10, 2014 – Mymetics announced today that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP.

Dr. Mario Amacker recently joined Mymetics as Head of Quality and Manufacturing, after having been member of the executive management team and head of process development and manufacturing at Pevion Biotech SA. Dr Amacker brings a wealth of experience and know-how in the manufacturing, formulation and quality aspects of influenza based virosomes and is a very strong addition to the Mymetics management team.

Pevion Biotech SA was the exclusive manufacturer for Mymetics' clinical stage HIV and malaria virosome vaccine candidates until they stopped operations. Consequently Mymetics has further secured the freedom to manufacture and obtained exclusive rights to the know-how, IP and materials related to the manufacturing of the promising HIV and malaria virosome based vaccines.

"We are very proud that Dr. Mario Amacker has decided to join Mymetics. He perfectly complements our strong scientific team: Dr. Toon Stegmann, CSO of Mymetics BV and Head of R&D and Dr. Sylvain Fleury, the CSO of Mymetics Corporation" said Ronald Kempers, CEO of Mymetics Corporation. "With our recently announced license and collaboration agreement for the RSV virosome vaccine, financed by Astellas Pharma, one of the two leading pharmaceutical company in Japan, we are on the right track to build a solid but nimble virosome vaccine research and development company, with a strong pipeline of very promising prophylactic vaccine candidates for specific infectious diseases".

About Mymetics

Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTC BB: MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath – Astellas). The company's HIV-1 vaccine has completed a Phase I clinical trial in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase.

For further information, please visit www.mymetics.com.

Contact

Ronald Kempers
CEO
Mymetics Corporation
Tel: +41 21 653 4535

Press release

Media

Christophe Lamps

Senior Partner

Dynamics Group

Mobile: + 41 79 476 26 87

Email: cla@dynamicsgroup.ch

Forward-looking statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.